Flubendazole as a macrofilaricide: History and background.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): Geary TG;Geary TG; Mackenzie CD; Mackenzie CD; Silber SA; Silber SA
  • Source:
    PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2019 Jan 16; Vol. 13 (1), pp. e0006436. Date of Electronic Publication: 2019 Jan 16 (Print Publication: 2019).
  • Publication Type:
    Journal Article; Review
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101291488 Publication Model: eCollection Cited Medium: Internet ISSN: 1935-2735 (Electronic) Linking ISSN: 19352727 NLM ISO Abbreviation: PLoS Negl Trop Dis Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Elephantiasis, Filarial/*drug therapy ; Filaricides/*therapeutic use ; Mebendazole/*analogs & derivatives ; Microfilariae/*drug effects ; Onchocerca volvulus/*drug effects ; Onchocerciasis/*drug therapy ; Wuchereria bancrofti/*drug effects; Albendazole/therapeutic use ; Animals ; Diethylcarbamazine/therapeutic use ; Elephantiasis, Filarial/parasitology ; Elephantiasis, Filarial/transmission ; Gastrointestinal Diseases/drug therapy ; Gastrointestinal Diseases/parasitology ; Humans ; Ivermectin/therapeutic use ; Mebendazole/therapeutic use ; Onchocerciasis/parasitology ; Onchocerciasis/transmission
    • Abstract:
      Benzimidazole anthelmintics have long been employed for the control of soil-transmitted helminth infections. Flubendazole (FBZ) was approved in 1980 for the treatment of gastrointestinal nematode infections in both veterinary and human medicine. It has also long been known that parenteral administration of FBZ can lead to high macrofilaricidal efficacy in a variety of preclinical models and in humans. As part of an effort to stimulate the discovery and development of new macrofilaricides, particularly for onchocerciasis, research has recently been devoted to the development of new formulations that would afford high oral bioavailability of FBZ, paving the way for potential clinical development of this repurposed drug for the treatment of human filariases. This review summarizes the background information that led to this program and summarizes some of the lessons learned from it.
      Competing Interests: I have read the journal’s policy, and the authors of this manuscript have the following competing interests: SAS is an employee of Johnson & Johnson. Both TGG and CDM have served as consultants for Johnson & Johnson for some aspects of the work described in this submission.
    • References:
      PLoS Negl Trop Dis. 2019 Jan 16;13(1):e0007026. (PMID: 30650076)
      J Infect Dis. 2015 Sep 1;212(5):684-93. (PMID: 25657255)
      Int J Parasitol Drugs Drug Resist. 2015 Jul 07;5(3):135-40. (PMID: 26288741)
      Sci Rep. 2017 Mar 16;7(1):210. (PMID: 28303006)
      Clin Infect Dis. 2016 Feb 1;62(3):334-341. (PMID: 26486704)
      PLoS Negl Trop Dis. 2019 Jan 16;13(1):e0006787. (PMID: 30650084)
      PLoS Negl Trop Dis. 2016 May 04;10(5):e0004698. (PMID: 27145083)
      PLoS Negl Trop Dis. 2015 Feb 20;9(2):e0003534. (PMID: 25700363)
      Reprod Toxicol. 2014 Nov;49:33-42. (PMID: 24994687)
      Reprod Toxicol. 2013 Apr;36:78-87. (PMID: 23287076)
      Lancet. 1997 Jul 5;350(9070):18-22. (PMID: 9217715)
      J Vet Pharmacol Ther. 2017 Oct;40(5):493-499. (PMID: 28092103)
      Lancet. 1983 Jan 22;1(8317):139-43. (PMID: 6130195)
      PLoS Negl Trop Dis. 2014 May 29;8(5):e2838. (PMID: 24874646)
      PLoS Negl Trop Dis. 2017 Jan 5;11(1):e0005163. (PMID: 28056015)
      Int J Parasitol Drugs Drug Resist. 2016 Dec;6(3):288-296. (PMID: 27733308)
      Parasitology. 2014 Jan;141(1):119-27. (PMID: 23866958)
      Int J Parasitol Drugs Drug Resist. 2016 Dec;6(3):272-286. (PMID: 27693536)
      Curr Opin Infect Dis. 2012 Dec;25(6):709-17. (PMID: 23041774)
      Infect Dis Poverty. 2016 May 24;5(1):54. (PMID: 27388873)
      Am J Trop Med Hyg. 2018 Jan;98(1):21-26. (PMID: 29141764)
      PLoS Negl Trop Dis. 2019 Jan 16;13(1):e0006320. (PMID: 30650105)
      PLoS Negl Trop Dis. 2015 May 21;9(5):e0003703. (PMID: 25996946)
      Expert Rev Anti Infect Ther. 2011 Aug;9(8):681-95. (PMID: 21819332)
      Filaria J. 2003 Oct 24;2 Suppl 1:S10. (PMID: 14975067)
      Mutagenesis. 2016 May;31(3):309-21. (PMID: 26443851)
      J Pharm Sci. 2016 Sep;105(9):2782-2793. (PMID: 27113473)
      Expert Rev Anti Infect Ther. 2011 May;9(5):497-501. (PMID: 21609260)
      Lancet. 2010 Oct 2;376(9747):1175-85. (PMID: 20739055)
    • Accession Number:
      0 (Filaricides)
      70288-86-7 (Ivermectin)
      81G6I5V05I (Mebendazole)
      F4216019LN (Albendazole)
      R8M46911LR (flubendazole)
      V867Q8X3ZD (Diethylcarbamazine)
    • Publication Date:
      Date Created: 20190117 Date Completed: 20190214 Latest Revision: 20231005
    • Publication Date:
      20250114
    • Accession Number:
      PMC6334891
    • Accession Number:
      10.1371/journal.pntd.0006436
    • Accession Number:
      30650160